{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:01:47Z","timestamp":1747180907011,"version":"3.40.5"},"reference-count":6,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health University of Iowa"},{"name":"Mayo Clinic Lymphoma SPORE","award":["CA97274"],"award-info":[{"award-number":["CA97274"]}]},{"name":"MJM"},{"name":"TMH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1093\/annonc\/mdy492","type":"journal-article","created":{"date-parts":[[2018,10,31]],"date-time":"2018-10-31T20:14:58Z","timestamp":1541016898000},"page":"153","source":"Crossref","is-referenced-by-count":0,"title":["Reply to the letter to the editor \u2018Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting\u2019 by van der Gali\u00ebn et al."],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1867-0526","authenticated-orcid":false,"given":"M.J.","family":"Maurer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1093\/annonc\/mdy492_bb0010","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/annonc\/mdy482","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting","volume":"30","author":"van der Gali\u00ebn","year":"2019","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy492_bb0015","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/annonc\/mdy203","article-title":"Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials","volume":"29","author":"Maurer","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdy492_bb0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdy492_bb0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2016.70.0765","article-title":"Minimal loss of lifetime for patients with diffuse large B-cell lymphoma in remission and event free 24 months after treatment: a Danish population-based study","volume":"35","author":"Jakobsen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdy492_bb0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/ajh.25147","article-title":"Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma","volume":"93","author":"Ekberg","year":"2018","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1093\/annonc\/mdy492_bb0035","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","article-title":"Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient\u2013level analysis of multiple randomized trials (SEAL)","volume":"36","author":"Shi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419309962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419309962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/1\/153\/27511381\/mdy492.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T08:45:50Z","timestamp":1624697150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419309962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":6,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0923753419309962"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy492","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}